Our trade recommendation tool can cross-verify current
analyst consensus on GT Biopharma and to analyze the company potential to grow this quarter and beyond.
About
14.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.26. Some equities with similar Price to Book (P/B) outperform the market in the long run. GT Biopharma recorded a loss per share of
6.45. The entity had not issued any dividends in recent years. The firm had
a split on the 11th of February 2021.
The successful prediction of GT Biopharma
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as GT Biopharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of GT Biopharma based on GT Biopharma hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to GT Biopharma's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to GT Biopharma's related companies.
Use Technical Analysis to project GTBP expected Price
GT Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of GT Biopharma technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of GT Biopharma trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...GT Biopharma Gross Profit
GT Biopharma Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing GT Biopharma previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show GT Biopharma Gross Profit growth over the last 10 years. Please check GT Biopharma's
gross profit and other
fundamental indicators for more details.
Breaking down GT Biopharma Further
Net Loss for the year was (28.3
M).
| 2020 | 2021 (projected) |
Interest Expense | 3 M | 4.68 M | Gross Profit | 31.05 K | 25.32 K |
Cost of Revenue Breakdown
GT Biopharma Cost of Revenue yearly trend continues to be very stable with very little volatility. Cost of Revenue is likely to drop to about 51
K. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. GT Biopharma Cost of Revenue is very stable at the moment as compared to the past year. GT Biopharma reported last year Cost of Revenue of 51,300
| 2010 | 57,000 |
| 2020 | 51,300 |
| 2021 | 51,000 |
Momentum Analysis of GT Biopharma suggests possible reversal in June
Recent total risk alpha is at -2.34.
As of the 17th of May 2021, GT Biopharma owns the Market Risk Adjusted Performance of 54.75,
semi deviation of 5.43, and Standard Deviation of 115.28. GT Biopharma
technical analysis makes it possible for you to employ past data patterns with the intention to determine a pattern that calculates the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume patterns, or the prices will eventually revert. We have analyzed nineteen
technical drivers for GT Biopharma, which can be compared to its peers in the sector. Please check out
GT Biopharma coefficient of variation, as well as the
relationship between the treynor ratio and
semi variance to decide if GT Biopharma is priced more or less accurately, providing market reflects its prevailing price of 12.51 per share. Given that GT Biopharma has
jensen alpha of 15.75, we strongly advise you to confirm GT Biopharma's latest market performance to make sure the company can sustain itself sooner or later.
The Bottom Line
Although few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, GT Biopharma may offer a potential longer-term growth to insiders. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor trade any shares of GT Biopharma at this time. The GT Biopharma risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to GT Biopharma.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of GT Biopharma. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
